Khaled Musallam/LinkedIn
Nov 20, 2025, 16:47
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Priviliged to be working with my friend Prof.Humaid Al-Shamsi to build on the strong foundations of BCI and lead the expansion of hematology services across the network, including dedicated programs in both classical (benign) and malignant hematology, and advanced cell and gene therapies through innovative clinical trials and strategic international partnerships with industry innovators.”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 18:27Are We Underestimating VTE After PanNET Surgery? – RPTH Journal
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58Early Diagnosis Can Change Everything in Hemophilia Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper